Clinical Study on New Injection Drug [123I] IIMU for Imaging Diagnosis of Cancer Begins – First-in-Human Studies to be Conducted

Research Press Release | June 24, 2014


Press Release
Key Points – [123I]IIMU is a compound that readily combines with thymidine phosphorylase, an enzyme strongly expressed in malignant tumors. This “seed” (candidate compound for development) is launched in universities and under development as a new injection drug for imaging diagnosis of cancer.

– A clinical study to verify safety of [123I]IIMU injection drug was approved by the Institutional Review Board of Hokkaido University Hospital for Clinical Research, and First-in-human studies*1 on healthy adults will begin for the first time in the world.

– Examinations using [123I]IIMU injection drug are expected to provide useful information that is difficult to obtain from other conventional methods, such estimation/determination of therapeutic effects of anticancer drugs, decision-making for a treatment plan, prognostic prediction, understanding of disease stages, and malignancy assessment.


*1: First-in-human study: During new drug development, evaluations are initially carried out on experimental animals through various studies. Efficacy and safety of the test drug are then evaluated on healthy human adult volunteers. This called the “first-in-human study” since the drug is administrated to humans for the first time in the world.

Overview Hokkaido University will begin an independent clinical study on [123I] IIMU, a new injection drug for imaging diagnosis of cancer, with Professor Nagara Tamaki of the Graduate School of Medicine as the general supervisor.

The [123I] IIMU injection drug for imaging diagnosis was newly developed by Professor Yuji Kuge and Lecturer Ken-ichi Nishijima of the Central Institute of Isotope Science/Graduate School of Medicine, Hokkaido University, and Professor Kazue Okura of the Graduate School of Pharmaceutical Sciences, Health Sciences University of Hokkaido. Efficacy and safety of the drug were evaluated in preclinical studies.*2 This is the first attempt in the world to administer this injection drug to healthy adults. The purpose of this clinical study is to evaluate the safety of [123I] IIMU injection drug for imaging diagnosis.

Examinations using this injection drug for imaging diagnosis are expected to result in the detection and imaging of the activation of thymidine phosphorylase, an enzyme strongly expressed in malignant tumors, from outside the body, as well as provide new information useful in the diagnosis/treatment of cancer patients.


*2: Preclinical study: Preliminary study is carried out before the first-in-human study, where the pharmacology (drug actions) and pharmacokinetics (drug behaviors within the body) are evaluated using experimental animals.

Inquiries

Yuji Kuge, Professor, Graduate School of Medicine, Hokkaido University

TEL: +81-11-706-6087

FAX: +81-11-706-7862

E-mail:IIMU@ric.hokudai.ac.jp

Japanese

Link

新しいがんの画像診断用注射薬,[123I]IIMU の臨床研究を開始~First-in-human 試験実施へ~

LATEST NEWS

University News | December 15, 2017
Hokkaido Summer Institute 2018 courses finalized!
University News | December 13, 2017
Japan-Russia Youth Forum 2017 held at Hokkaido University
University News | December 01, 2017
HU Ambassador wins the 2017 Volvo Environmental Prize
University News | November 13, 2017
Dinner meeting with Indonesian alumni
Student Awards | November 10, 2017
Student Awards: Graduate School of Medicine

ARCHIVES

CONNECT WITH US

  • Facebook
  • Twitter
  • Instagram
  • YouTube
  • LinkedIn

BACK TO TOP